Vividion Therapeutics Inc. has patented 2-azaspiro[3.3]heptane derivatives acting as signal transducer and activator of transcription 3 (STAT3) inhibitors potentially useful for the treatment of cancer.
Insilico Medicine Inc. has synthesized cyclin-dependent kinase 8/19 (CDK8/19) dual inhibitors reported to be useful for the treatment of autoimmune disease and cancer.
A new series of proteolytic targeting chimeras (PROTACs) was designed by Zhejiang University of Technology scientists based on a previously described PD-L1 inhibitor, and systematic screening of ligands and linkers, combined with structure-activity relationship analysis of the degraders, led to the identification of compounds [I] and [II] as the most active candidates.
Suzhou Ribo Life Science Co. Ltd. recently reported on the development and preclinical characterization of a novel blood-brain barrier (BBB)-penetrating oligonucleotide drug, RBD-8088, for the treatment of glioblastoma.
Repair Biotechnologies Inc. and Genevant Sciences Corp. have entered into a collaboration and nonexclusive license agreement to combine Repair’s Cholesterol Degrading Platform (CDP) mRNA technology with Genevant’s proprietary lipid nanoparticle (LNP) technology in the development of a potential novel treatment for atherosclerosis.
Researchers from Maruho Co. Ltd. published data regarding the development and preclinical evaluation of a novel orally available bromodomain-containing protein 4 (BRD4) inhibitor for the treatment of melanoma.
Endometrial cancer (EC) accounts for 20% to 30% of most malignant tumors of the female reproductive system, making it one of the most common. Furthermore, the 5-year survival rate of patients with early-stage EC is 90%, but this number decreases to 20% in late-stage disease.
H. Lundbeck A/S and Iambic Therapeutics Inc. have entered into a strategic research collaboration focused on the discovery of a small-molecule therapeutic for the treatment of migraine. The collaboration will leverage Iambic’s artificial intelligence (AI)-powered drug discovery platform.